BAGNEUX, France--(BUSINESS WIRE)--Regulatory News:
Genomic Vision (GV: EN Paris) (Paris:GV), a French molecular diagnostics company specializing in the development of diagnostic tests for genetic diseases and cancers based on molecular combing technology, announced today that the Company management will be participating at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference taking place February 10-11, 2016 in New York City. Chief Executive Officer Aaron Bensimon, Ph.D., will present a corporate overview at 2:45 PM Eastern time on February 10th.
The Source Conference presentation will be webcast and can be found on the Company’s website www.genomicvision.com or at the following hyperlink, Genomic Vision Source Conference Webcast.
ABOUT GENOMIC VISION
Founded in 2004, Genomic Vision is a molecular diagnostics company specialized in the development of diagnostic tests for genetic diseases and cancers based on molecular combing. Using this innovative technology that allows the direct visualization of individual DNA molecules, Genomic Vision detects quantitative and qualitative variations in the genome that are at the origin of numerous serious pathologies. The Company is developing a solid portfolio of tests that notably target breast cancer and cancer of the colon. Since 2013, the Company has marketed the CombHeliX FSHD test for identifying a myopathy that is difficult to detect, Facio-scapulo-humeral dystrophy (FSHD), in the United States thanks to a strategic alliance with Quest Diagnostics, the American leader in diagnostic laboratory tests, and in France. Genomic Vision has been listed on Compartment C of Euronext Paris since April 2014.
For further information, please go to www.genomicvision.com
Member of CAC® Mid & Small, CAC® All-Tradable and EnterNext© PEA-PME 150 indexes
